Endothelial cells (ECs) undergo a finite number of cell divisions before growth arrest or replicative senescence, modulated in part by the proinflammatory cytokine, interleukin-1 (IL-1). IL-1 and its family members are expressed in human atherosclerotic vessels, mainly in the endothelium. EC replicative senescence and IL-1 have been associated with atherosclerosis. Genetic variants at the IL-1 locus have been associated with a variety of coronary phenotypes. In this study, we examined the relationship between the interleukin-1 receptor antagonist variable number tandem repeat allele 2 (IL-1RN*2*2) and EC replicative capacity. A significant decrease in EC cumulative population doublings (CPDs) was associated with the rare allele (IL-1RN*2*2) at IL-1RN, 8.56؎0.97 (n‫)7؍‬ versus 13.14؎1.00 (IL-1RN*1*1, n‫,)02؍‬ P‫.8110.0؍‬ Proliferation of IL-1RN*2*2 ECs detected by Ki67 expression was also significantly reduced particularly at later passage, passage 6: 21.76؎0.93% (n‫)6؍‬ versus 48.10؎8.81% (IL-1RN*1*1, n‫)7؍‬ (P‫)3230.0؍‬ and passage 8: 22.48؎3.08% (n‫)6؍‬ versus 42.29؎3.06% (IL-1RN*1*1, n‫)7؍‬ (P‫.)8200.0؍‬ IL-1RN*2 carriage was associated with increased numbers of senescent ECs. Basal apoptosis, telomerase activity, and telomere length were not different with respect to IL-1RN genotype. Addition of exogenous IL-1ra (1 ng/mL) increased CPDs in a number of human umbilical vein endothelial cell cultures and increased proliferating cells from 12.11؎1.21% to 27.82؎2.82% (P‫,6120.0؍‬ IL-1RN*2*2, passage 8, n‫.)2؍‬ These data suggest genetic control of EC proliferation and life span by the IL-1 locus and imply that IL-1ra may have a function connected with EC growth.
C oronary artery disease (CAD) has a substantial inflammatory component, 1 which is in part genetic. 2 Arterial inflammation, in the context of atherosclerosis, may be partially mediated by interleukin-1 (IL-1) and IL-1-related cytokines. IL-1 causes multiple responses within the vessel wall including inhibition of EC proliferation 3 and induction of adhesion molecule expression promoting leukocyte infiltration. 4 IL-1 exerts its effects via the type I IL-1 receptor, which is blocked by the endogenous, nonsignaling receptor antagonist (IL-1ra).
A gene variant at IL-1RN has been associated with chronic inflammatory disorders including angiographic single vessel coronary disease 2 and protection from restenosis after percutaneous transluminal coronary angioplasty 5 and stenting. 6 The functional consequences of the IL-1RN gene variant appear complex. The less common allele (2) is associated with decreased levels of intracellular (ic) IL-1ra in endothelial cells (ECs). 7 IL-1 has been linked with EC life span in culture. As ECs age, IL-1 accumulates, and antisense oligonucleotides to IL-1␣ extend EC life span. 8, 9 We speculate that ECs with lower amounts of the natural antagonist of IL-1 might have an attenuated life span in culture.
Materials and Methods

Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated and cultured as described. 7 Population doublings were calculated at each passage until growth arrest: log 10 cells harvestedϪlog 10 cells plated/log 10 2.
Exogenous secreted IL-1ra (1 ng/mL or 100 ng/mL) (Amgen) was added to paired HUVEC cultures at 2-to 3-day intervals from onset of culture; proliferation and cumulative population doublings (CPDs) were calculated as described.
DNA Isolation and IL-1RN Genotyping
Genomic DNAs isolated from HUVECs were genotyped at IL-1RN (86 bp, variable number tandem repeat, intron 2) as described. 2 The common 4 repeat polymorphism was designated allele 1 (*1); the less common 2 repeat, allele 2 (*2).
Ki67 Proliferation Marker
Ki67, a proliferation-related antigen, was used to determine the proliferating fraction of ECs as detailed. 10 Ki67-positive cells were counted in 5 random fields of view.
Detection of Senescence and Apoptotic HUVECs
Senescence-associated (SA) ␤-galactosidase (␤-Gal) staining 11 and terminal transferase-mediated dUTP nick-end labeling (TUNEL) were used to detect senescent and apoptotic HUVECs, respectively.
Telomere Length and Telomerase Activity Assay
Genomic DNAs (5 g) digested overnight at 37°C with RsaI/HinfI (Promega) were separated on a 0.6% agarose gel, transferred to a Hybond N ϩ membrane (Amersham) and hybridized with 32 P-labeled 5Ј(TTAGGG) 6 at 65°C. Bound oligonucleotide was detected by exposure to XAR-Omat film (Kodak).
The telomerase assay is detailed in the online data supplement (available online at http://www.circresaha.org).
Results
EC length of life in culture, assessed as CPDs, calculated from the onset of culture until growth arrest, showed significant association with IL-1RN genotype: any carriage *2, 10.19Ϯ0.86 (nϭ24) versus *1*1, 13.14Ϯ1.00, (nϭ20), Pϭ0.0259. Homozygosity for *2 was associated with mean significant attenuation of life span: *2*2, 8.56Ϯ0.97 (nϭ7) versus *1*1, 13.14Ϯ1.00 (nϭ20), Pϭ0.0118 ( Figure 1A) . No association was apparent with CPDs and other polymorphisms of the IL-1 gene cluster (data not shown). HUVECs conformed to the characteristic senescent phenotype described by Maciag et al 12 with increasing passage.
Decreased expression of Ki67 was associated with IL-1RN genotype at passage 6: 21.76Ϯ0.93% (*2*2, nϭ6) versus 48.10Ϯ8.81% (*1*1, nϭ7) (Pϭ0.0323) and passage 8: 22.48Ϯ3.08% (*2*2, nϭ6) versus 42.29Ϯ3.06% (*1*1, nϭ7) (Pϭ0.0028) ( Figure 1B ). SA-␤-Gal staining was not statistically associated with IL-1RN*2 carriage (nϭ17) compared with wild type (nϭ10); there was a trend at passages 6 and 7, P6 55.32Ϯ10.00% (*2 carriage) versus 42.89% (1*1*) and P7, 59.45Ϯ10.30% versus 32.36% (PϭNS) (online Figure 1 , see online data supplement).
An index of apoptotic nuclei showed no association with IL-1RN*2*2 (nϭ6, PϭNS) (online Figure 2) .
We investigated whether a change in telomere length was associated with reduced CPDs at the end of life in ECs of different genotypes. Importantly, the IL-1RN genotypes of HUVECs (*1,*1 and *2,*2) had the same telomere length at the start of culture, and although there was a gradual reduction in length with passage, we observed no association with genotype (nϭ2, Figure 2 ). Since telomerase activity may abrogate telomere loss, we investigated telomerase activity in IL-1RN*2*2 HUVECs and showed no apparent reduction in activity (nϭ3, online Figure 2 ). These data suggest a telomerase-independent mechanism of EC cell survival under the conditions studied.
Since the only known function of IL-1ra is to block IL-1mediated events, the replicative capacity of ECs in response to continuous addition of exogenous IL-1ra (1 ng/mL) throughout EC life span was examined. Proliferation (Ki67 expression) was increased in HUVECs (IL-1RN*2*2) continually treated with IL-1ra: passage 7, no IL-1ra 12.39Ϯ3.95% versus ϩIL-1ra 22.29Ϯ6.37%), Pϭ0.0763 (nϭ2); passage 8, no IL-1ra 12.11Ϯ1.21% versus ϩIL-1ra 27.82Ϯ2.82%, Pϭ0.0216 (nϭ2) (Figure 3 ). Mean CPDs were increased in some HUVEC cultures in response to 1 ng/mL IL-1ra (nϭ7) 25.51Ϯ2.03 versus untreated controls 20.56Ϯ2.03 (Pϭ0.018); this increase was not observed with 100 ng/mL IL-1ra (nϭ7).
Discussion
The results of the present study suggest a link between IL-1RN genotype and the growth dynamics of HUVECs in vitro with a reduction in EC growth potential associated with IL-1RN*2. The rare allele *2 at IL-1RN is known to be associated with lower production of icIL-1ra protein in HUVECs. 7 A similar observation was made for columnar epithelial cells in ulcerative colitis. 13 We report that carriage of allele 2 (IL-1RN*2) at IL-1RN is associated with decreased CPDs and proliferation in HUVECs. Addition of exogenous IL-1ra restores the proliferative potential of HUVECs with IL-1RN*2*2 to levels observed with IL-1RN*1*1 and extends CPDs in selected HUVEC cultures. It is known that IL-1 inhibits EC proliferation; we propose that IL-1 released after senescence binds available IL-1Rs, thus decreasing proliferation. Addition of exogenous IL-1ra may block IL-1 signaling and extend EC life span. This mechanism could partly explain the change in proliferation observed at later passages in IL-1RN*2*2 ( Figure 3) .
These data suggest that decreased proliferation seen in IL-1RN*2*2 HUVECs occurs, in part, as a result of an increase in senescence rather than apoptosis. EC senescence has previously been shown to be associated with reduced telomere length and telomerase activity 14, 15 ; these did not appear to be associated with IL-1RN genotype in this study.
Although the specific cellular mechanism for reduction of EC proliferation in relation to genotype remains to be determined, we suggest that IL-1RN*2*2 genotype leads to low levels of icIL-1ra in ECs causing an imbalance of IL-1 family members favoring IL-1 agonistic activity. This may regulate the activity of cell cycle components including p21. 16 These data also demonstrate telomere-independent control of EC proliferative capacity and life span, by genetic variation at the IL-1 locus.
These data may have important implications for the role of IL-1 in vessel wall homeostasis and atherosclerotic and inflammatory diseases.
EC turnover is increased under conditions that favor atherogenesis (hypertension, high cholesterol levels, and anatomical branch points). The accelerated development of a dysfunctional or senescent phenotype under these conditions is plausibly associated with atherogenesis or the clinical presentation of atherosclerosis. Of relevance to this are the data that the IL-1RN*2 allele is associated with atherosclerotic coronary disease.
Although we favor the hypothesis that allele 2 of IL-1RN, in association with reduced IL-1ra production, is a central mechanism for the observed cell biological association reported, it is acknowledged that the mechanism of reduced IL-1ra production under these conditions remains unclear and requires further study.
In summary, it appears that the IL-1RN*2 allele is at the very least a marker for an EC phenotype plausibly associated with vascular disease. 
